Leonabio enrolls 500th subject in Phase 3 Elaine-3 trial
Leonabio enrolled its 500th subject in Phase 3 Elaine-3 for lasofoxifene with abemaciclib, according to an SEC filing.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.